The current stock price of ISRG is 542.32 USD. In the past month the price decreased by -4.1%. In the past year, price increased by 0.51%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.14 | 218.16B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.38 | 137.24B | ||
| SYK | STRYKER CORP | 26.89 | 135.41B | ||
| BDX | BECTON DICKINSON AND CO | 13.93 | 57.34B | ||
| IDXX | IDEXX LABORATORIES INC | 55.84 | 56.23B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.33 | 48.21B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.29 | 38.25B | ||
| RMD | RESMED INC | 25.48 | 36.82B | ||
| DXCM | DEXCOM INC | 36 | 26.12B | ||
| PODD | INSULET CORP | 64.7 | 20.80B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.32 | 18.15B | ||
| HOLX | HOLOGIC INC | 17.56 | 16.72B |
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. The company is headquartered in Sunnyvale, California and currently employs 15,638 full-time employees. The company went IPO on 2000-06-13. The firm specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
INTUITIVE SURGICAL INC
1020 Kifer Road
Sunnyvale CALIFORNIA 94086 US
CEO: Gary S. Guthart
Employees: 15638
Phone: 14085232100
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. The company is headquartered in Sunnyvale, California and currently employs 15,638 full-time employees. The company went IPO on 2000-06-13. The firm specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
The current stock price of ISRG is 542.32 USD. The price decreased by -0.92% in the last trading session.
ISRG does not pay a dividend.
ISRG has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
INTUITIVE SURGICAL INC (ISRG) has a market capitalization of 192.25B USD. This makes ISRG a Large Cap stock.
INTUITIVE SURGICAL INC (ISRG) will report earnings on 2026-01-21, after the market close.
The outstanding short interest for INTUITIVE SURGICAL INC (ISRG) is 2.12% of its float.
ChartMill assigns a technical rating of 6 / 10 to ISRG. When comparing the yearly performance of all stocks, ISRG is one of the better performing stocks in the market, outperforming 74.47% of all stocks.
ChartMill assigns a fundamental rating of 7 / 10 to ISRG. ISRG has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Over the last trailing twelve months ISRG reported a non-GAAP Earnings per Share(EPS) of 8.61. The EPS increased by 28.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.58% | ||
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| Debt/Equity | 0 |
40 analysts have analysed ISRG and the average price target is 613.44 USD. This implies a price increase of 13.11% is expected in the next year compared to the current price of 542.32.
For the next year, analysts expect an EPS growth of 20.12% and a revenue growth 21.33% for ISRG